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Summary This study compared inspiratory characteristics of the Novolizers and
Turbuhalers. Sixty patients with obstructive lung disease (40 asthmatics, 20 patients
with COPD) and without DPI experience were enrolled into this investigator
initiated, randomized, cross-over study. Collected data of 56 patients were eligible
for analysis. Inspiratory pressure and inspiratory flow through both devices were
measured in every patient using a double-beam oscilloscope. Peak inspiratory flow
(PIF), duration of inspiratory flow 460 l/min and increase in inspiratory pressure
were significantly higher in the Novolizers group. In addition, the inspiratory flow
rate 0.1 s after beginning of inhalation was over two-times higher at inhalation
through the Novolizers compared to inhalation through the Turbuhalers. The
Turbuhalers data, but not the Novolizers data, showed a significant negative
correlation between lung function and inspiratory flow. The dynamic resistance of
the Turbuhalers was 5.5-times higher than that of the Novolizers. Patients using the
Turbuhalers had to invest a significantly higher inspiratory effort compared to the
use of the Novolizers in order to achieve the same inspiratory flow (e.g., 60 l/min).
Indeed, more than 40% of the patients in the Turbuhalers group failed to reach an
inspiratory flow of 60 l/min. Overall, patients inhaling through the Novolizers had a
better inhalation performance than those inhaling through the Turbuhalers.
& 2004 Published by Elsevier Ltd.
Introduction
The choice of inhaler device should be an integral
part of obstructive lung disaese management
decisions. Pressurized metered-dose inhalers
(pMDIs) are the most popular devices for adminis-
tering drugs for inhalation. However, more than 80
countries have signed the Montreal Protocol to ban
the production of chlorofluorocarbons (CFCs) in the
next few years1 which necessitates the replace-
ment of CFC-propelled pMDIs with other aerosol
delivery devices. Among the alternative means of
delivering therapeutic aerosols, dry powder inha-
lers (DPIs) are gaining popularity and acceptance.
Crystalline or powder drugs for inhalation are
inexpensive, do not depend on the use of CFC and
do not require coordination between inhalation and
device activation. Recent improvements in the
design, ease of use, and multidose capability make
DPIs attractive alternatives to pMDIs for aerosol
therapy in patients with asthma.2
For the delivery of a therapeutic agent from
an inhalation device to the lungs, a high quality
aerosol with a small particle size (diameter 2–5mm)
must be generated. If the particles are larger than
that, they are deposited in the upper airways and in
the mouth. If they are smaller, they cannot be
deposited in the lungs, therefore they are exhaled.
With pMDIs, the energy required to aerosolize drug
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particles within the device ready for inhalation by
the patient is propellant-generated. However, with
DPIs the drug powder must be desagglomerated into
respirable particles. The initiation of this starts
with the inhalation procedure itself (i.e., the
pressure and flow that a patient generates through
the device during the inhalation maneuver). In fact,
doubling the inspiratory velocity quadruples the
energy generated.
There are several dry powder inhaler devices on
the market, characterized as single dose devices or
multiple dose devices based on a reservoir system
or premetered doses. The Novolizers (VIATRIS,
Frankfurt, Germany) and the Turbuhalers (Astra-
Zeneca, Lund, Sweden) are two reservoir multiple
dose dry powder inhalers (MDPIs), both of which
deliver the inhaled corticosteroid budesonide.
However, the intrinsic resistance of the Turbuha-
lers is higher than that of the Novolizers. The aim
of this study was to compare inspiratory character-
istics as well as inspiratory characteristic reprodu-
cibility of the Novolizers and the Turbuhalers in
patients without DPI experience and to assesses the
effect of time point of instructions for use on
patient performance.
Materials and methods
Patients
Sixty patients with obstructive lung disease (40
asthmatics and 20 COPD patients) were enrolled
into the study. None of the patients had used a dry
powder device previously, but used a pMDI or no
inhalative asthma therapy. Collected data of 56
patients were eligible for analysis. Patient char-
acteristics are shown in Table 1. Patients gave their
written informed consent before being enrolled
into the study.
Study design
This investigator-initiated study had a randomized
cross-over design. Before starting data collection,
patients received instructions according to the
instructions for use brochures for both the Turbu-
halers and the Novolizers. In both cases a placebo
inhalation device without the relevant drug for-
mulation (i.e., budesonide) was used. Every patient
inhaled at least two times through each of the two
devices in randomized order. The following flow
and pressure variables were measured for each
device using a double-beam oscilloscope (Velleman
Storage Scope for PC, sampling rate 20MHz),
Spiroceptor (Siemens) plugged to an Ellison pres-
sure transducer (ESI, UK), Keller pressure sensor
(Keller, Switzerland) (Fig. 1): peak inspiratory flow
(PIF; l/s); time to peak inspiratory flow (s);
inspiratory flow at 0.1 s post-inhalation (P0.1; l/s);
duration of inspiratory flow 430 l/min and 460 l/
min (s) respectively; peak inspiratory pressure
(kPa); and time to peak inspiratory pressure (s). A
first and second inspiratory maneuver was per-
formed with the Novolizers and the Turbuhalers,
respectively, recording peak inspiratory pressure,
time to PIF and time taken to reach an inspiratory
flow plateau in order to check for reproducibility.
The inspiratory characteristics of time to PIF, PIF,
peak pressure and duration of inspiratory flow
460 l/min were correlated with the lung function
variables forced expiratory volume in 1 s (FEV1,
%predicted) and the ratio of P0.1 and PIF.
Inhalation characteristics before and 6 weeks
after instruction were also recorded for both the
Novolizers and the Turbuhalers.
Statistics
Inspiratory characteristics of the devices, dynamic
resistance and within device reproducibility of
inspiratory characteristics were compared using
the Wilcoxon matched pairs test. Patient perfor-
mance with each device before and 6 weeks after
instruction was analysed using a combined t-test.
P-values p0.05 were judged to be significant.
Results
Inspiratory characteristics
Figure 2 shows an inspiratory flow and pressure
trace for both devices. For the Novolizers, peak
inspiratory pressure was achieved at approximately
10 cm H2O when patients noticed the acoustic
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Table 1 Patient baseline characteristics.
Patient characteristics
Sex 30 male, 30 female
Age (years) 49.9719.5
Weight (kg) 75.5717.1
Height (cm) 170.779.1
FEV1 (% predicted) 79.6720.1
Pimax (kPa) 9.779.3
P0:1 (kPa) 0.370.2
Results are presented as mean7standard deviation.
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feedback, the PIF was just over 60 l/min at
this pressure. However, a much higher inspira-
tory pressure was required through the Turbuha-
lers (approximately 70 cm H2O), and the PIF of
60 l/min was not completely reached at that
pressure.
Inspiratory flow and pressure characteristics are
summarized in Table 2. The PIF, duration of
inspiratory flow 460 l/min and increase in inspira-
tory pressure were all statistically significantly
higher in the Novolizers group compared to the
Turbuhalers group (Table 2). Patients in the
Novolizers group attained a PIF through the device
of approximately 80 l/min compared with just 55 l/
min for the Turbuhalers group. In this study on
patients without DPI experience using both devices
for the first time, eight patients (14.3%) in the
Novolizers group and 25 patients (44.6%) in the
Turbuhalers group failed to attain an inspiratory
flow rate of 60 l/min. Therefore, almost half of
these patients were unable to use the Turbuhalers
in an optimal way. By contrast, all patients inhaling
through the Novolizers were capable of generating
an inspiratory flow rate of min 30 l/min, but 5
patients (5.4%) in the Turbuhalers group failed to
reach even this inspiratory flow rate. In terms of
P0.1, the patients in the Novolizer
s group had more
than double the inspiratory flow rate of those in the
Turbuhalers group.
Correlation with lung function
There was no correlation between PIF, time to PIF,
peak inspiratory pressure or flow duration of
PIF460 l/min and FEV1 (% predicted) for either
the Novolizers or the Turbuhalers group. Similarly,
none of the inspiratory characteristics measured
through the Novolizers significantly correlated
with P0.1/PIF ratio. However, there was a significant
correlation between P0.1/PIF and both PIF
(Po0:000164) as well as time at which inspiratory
flow was 460 l/min (Po0:011182) for the Turbu-
halers group.
Inspiratory characteristics reproducibility
and device resistance
The reproducibility of the inhalation in the same
patient using the same device did not show any
statisticallysignificantdifferencesfortheNovolizers
or the Turbuhalers for the variables of peak
pressure, time to PIF and time to inspiratory
flow plateau. The dynamic resistance of the
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Figure 1 Double-beam oscilloscope used to measure flow and pressure characteristics of the Novolizers and the
Turbuhalers. Flow is measured by a spiroceptor, pressure is directly taken through a hole in the Novolizers or
Turbuhalers mouthpiece; hole diameter and tubing are the same for all experiments; the PC-Oscilloscope registration
could not be seen by the patient.
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Turbuhalers was 28.45 cm H2O.s/l, 5.5 times higher
to that for the Novolizers (5.07 cmH2O.s/l)
(Po0:000001).
Effect of patient instruction
Patients’ inhalation characteristics showed remark-
able similarity before instruction and 6 weeks after
instruction and did not significantly change during
that time for either the Novolizers or the
Turbuhalers (Table 3).
Discussion
This study showed that the patients’ inhalation
performance through the Novolizers was superior
to that through the Turbuhalers. PIF and flow
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Figure 2 Sample flow and pressure characteristics obtained from one patient inhaling through the Novolizers (A) and
the Turbuhalers (B). (A) Original registration of three maneuvers with the Novolizers; peak pressure of about 10 cm
H2O to open the flap of the Novolizer
s, the resulting pressure drop and then a constant inspiratory pressure of about
7 cm H2O which is mirrored in a constant flow rate. (B) Original registration of four maneuvers of pressure and flow in
the Turbuhalers in a patient with optimal performance; same scale as in figure (A); the higher and the lower pressure
and shorter resulting flow in comparison to the Novolizers.
Table 2 Peak inspiratory flow and pressure characteristics achieved by patients with obstructive lung disease (40
asthmatics and 16 COPD patients), n ¼ 56 inhaling through the Novolizers and through the Turbuhalers.
Inspiratory variable Novolizers Turbuhalers Wilcoxon matched pairs test
Peak inspiratory flow PIF (l/min) 79.8719.2 54.3716.8 Po0:000001
Flow 460 l/min (s) 0.7770.52 0.3370.50 Po0:000004
Flow 430 l/min (s) 1.4570.57 1.4970.82 Po0:172232
Peak pressure (cm H2O) 6.5471.56 26.26711.44 Po0:00001
Time to peak pressure (s) 0.3870.23 0.5770.24 Po0:004453
Inspiratory resistance (cm H2O.s/l) 5.0771.25 28.4578.16 Po0:000001
Results are presented as mean7standard deviation.
Inspiratory properties of DPIs S25
duration with PIF460 l/min were significantly high-
er for the Novolizers group, and intrinsic resis-
tance was significantly lower compared to that of
the Turbuhalers.
Many patients are unable to use their pMDIs
correctly.3 DPIs should be easier to use as they do
not require coordination of inhaler activation with
inhalation. However, patients without DPI experi-
ence and switching from pMDI to DPI tend to apply a
similar inhalation maneuver as with a pMDI, and
this may result in reduced peak inspiratory flow
rates. This aspect needs to be considered when
reviewing the results of the present investigation
which was conducted on a patient population
without DPI experience (pMDI or no inhalation
therapy). The Novolizers offers technical features
to these patients which optimize their inhalation
maneuver. Unlike the Turbuhalers, the Novolizers
guides the patient through the inhalation proce-
dure. Pressing down the dosage button initiates
premetering of a dose as well as a color change of
the indicator window from red to green telling the
patient that the device is ready for inhalation.
During inhalation, optical, acoustic and sensory
feedback mechanisms, with the first two of them
being linked to an inspiratory flow rate threshold of
35–50 l/min, inform the patient that inhalation
maneuver was correct. A dose counter informs the
patient about remaining doses and can be reset for
next counting only upon correct inhalation. These
features should increase the patient’s trust in DPI
use and make it easier to use. This fact was shown
in the present study as more patients in the
Turbuhalers group, after reading the instructions-
for-use brochure, were unable to use the inhaler
and exhaled into the device on at least one
occasion before inhalation. This is important as, if
patients exhale into the Turbuhalers before in-
halation, the drug is inadvertently released through
the air channels of the device and is not available
anymore for inhalation.
For all breath-activated devices the fine particle
fraction (FPF) is dependent on flow rate.4–9
Increasing the flow rate produces a greater amount
of drug delivered and increases the respirable
fraction from DPIs, the dose which a patient
inhales, and hence the effectiveness of the
therapeutic agent, depends upon the inspiration
capacity. For example, Hirsch and colleagues10
showed that the effectiveness of terbutaline-
induced bronchodilation was dependent on inspira-
tory capacity through the Turbuhalers. In the
present study, the mean PIF generated by selected
patients without DPI experience was 79.8 l/min
for the Novolizers compared with just 54.3 l/min
for the Turbuhalers. A flow rate of 80 l/min
through the Novolizers has previously been shown
to correspond to a FPF or respirable fraction of
34% of a 200 mg budesonide dose.9 Similarly, at
a flow rate of 60 l/min through the Pulmicort
Turbuhalers the FPF generated has been shown
to be about 21%. In other words, at the PIF
measured in the current study the Turbuhalers
emits about one third less respirable fraction of
therapeutic agent (i.e., budesonide) than the
Novolizers.
Flow during the initial part of the inspiratory
effort is important in determining the character-
istics of the aerosol generated by a DPI. For DPIs, a
minimal inspiratory flow must be achieved imme-
diately after the start of the inspiration maneuver
as desagglomeration of the powder takes place
before 0.1 s. In this study the flow rate achieved
through the Novolizers 0.1 s after the start of
inhalation was more than double of that achieved
through the Turbuhalers (Po0:00001). Therefore,
according to the equation E ¼ dP ¼ 12PV2; the
amount of energy generated by patients 0.1 s into
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Table 3 Peak inspiratory flow and pressure characteristics achieved by patients with obstructive lung disease
(n ¼ 56) inhaling through the Novolizers and through the Turbuhalers before and 6 weeks after instruction.
Novolizers Turbuhalers
Before
instruction
6 weeks
after
instruction
P-value Before
instruction
6 weeks
after
instruction
P-value
Time to peak
pressure (s)
0.4470.28 0.4470.25 o0.8914 0.4770.16 0.4870.15 o0.3115
Peak pressure (kPa) 6.2071.04 6.2170.93 o0.7867 25.2078.82 25.3077.73 o0.7550
Peak flow (l/s) 1.3070.32 1.3270.33 o0.4591 0.9270.29 0.9370.31 o0.8239
Flow time 460 l/min 0.7570.55 0.7770.56 o0.2395 0.3170.44 0.3470.43 o0.2276
Results are presented as mean7standard deviation.
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the inhalation maneuver was four times higher for
the Novolizers than for the Turbuhalers.
The importance of achieving a high inspiratory
flow at the start of the inhalation maneuver was
demonstrated by Everard and colleagues11 who
showed that with the Turbuhalers, the rate of
increase in flow significantly affected the particle
size distribution of the aerosol. Failure to attain a
flow rate of 30 l/min before 150ml of air had
passed through the device resulted in the aerosol
median particle diameter increasing from less than
6.6 mm to greater than 45.3 mm. Therefore, particle
size and hence the amount of drug delivered to the
lung from a DPI is dependent on both patient flow
rate and flow profile.
Patients’ lung function may affect how well they
can inhale through a device. In the present study
only in the Turbuhalers group inspiratory flow
negatively correlated with respiratory muscle
strain (i.e., patients with a high PO:1/PIF ratio
generated a low PIF and flow duration 460 l/min
and vice versa). This is likely due to the high
dynamic resistance of the Turbuhalers. By con-
trast, no significant correlation was observed
between lung function and any inspiratory char-
acteristic in the Novolizers group, suggesting
that it is equally effective in patients with mild
disease as well as those with more severe airflow
obstruction.
The Novolizers has been designed to offer low to
medium resistance on inhalation. By contrast, the
Turbuhalers has a high intrinsic resistance, requir-
ing a relatively high inspiratory flow of min. 60 l/
min for optimal drug delivery. In the present study
we found the intrinsic resistance of the Turbuha-
lers to be 5.5 times higher than that of the
Novolizers. Patients using the Turbuhalers must
invest a significantly higher inspiratory effort
compared to the use of the Novolizers in order to
achieve the same inspiratory flow (e.g., 60 l/min).
In fact almost half of the patients in this study
failed to reach an inspiratory flow rate of 60 l/min
when using the Turbuhalers. Others have also
shown problems in attaining high flow rates through
the Turbuhalers .12,13
Our study showed excellent within device repro-
ducibility with respect to inhalation characteris-
tics. Surprisingly, there was no difference in
patients’ inhalation characteristics before instruc-
tion and 6 weeks after instruction. These results
indicate that when introducing a patient into the
correct use of an inhalation device it is necessary to
monitor the patient closely, review his/her inhala-
tion technique, correct the technique, if necessary,
and repeat the instruction regularly, or to choose a
device that fits primarily to the patients inhalation
pattern otherwise it is likely that the patients will
lapse back into incorrect use of the device.
Conclusions
The present study showed that the instruction-for-
use brochure on its own might not be a sufficient
tool to train patients on correct DPI use. Every
patient needs to be instructed and ideally train
with a placebo device without drug powder before
starting inhalation therapy. There are important
differences between the devices regarding inhala-
tion characteristics. The Novolizers is a low to
medium resistance device. Patients inhaling
through the Novolizers are capable of generating
a higher PIF, P0.1 and increase in peak pressure
compared to patients inhaling through the Turbu-
halers. In addition, the Turbuhalers may not be
suitable for patients with severe airflow obstruc-
tion as the inspiratory flow generated through this
device is negatively correlated with patients’ lung
function. Patients using the Turbuhalers must
invest a much higher inspiratory effort compared
to the use of the Novolizers in order to overcome
the DPI’s intrinsic resistance and achieve the same
inspiratory flow (e.g., 60 l/min). Close monitoring
and repeated training are necessary to ensure that
patients continue to use their inhalers correctly.
For the delivery of medication to the lungs of
patients with obstructive lung disease, it is essen-
tial that an inhalation device is chosen which
closely matches the needs of the patient. The
results of the present study suggest that the
Novolizers, with its low to medium resistance and
superior inhalation characteristics, offers more
advantages to the ‘‘average patient’’ than the
Turbuhalers.
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